Arden Trust’s Lexicon Pharmaceuticals LXRX Stock Holding History

Arden Trust’s Portfolio LXRX Stock Details LXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-10,278	Closed	-$137K	–	646
2015 Q4	$137K	Buy	+10,278	New	+$126K	0.01%	617

Other funds holding LXRX

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

Ulys LLC New York $25.4M AUM 201.03% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Arden Trust's LXRX Position: Q1 2016 in Review

Arden Trust sold out of Lexicon Pharmaceuticals (LXRX) in Q1 2016, closing a stake of 10,278 shares — an estimated $137K sold.

Arden Trust first reported a position in LXRX in Q4 2015 and held it in 1 quarter. The position peaked at $137K in Q4 2015. 132 funds tracked by Wall St. Rank hold LXRX as of Q1 2016.

Arden Trust reported no remaining Lexicon Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
Arden Trust sold 10,278 Lexicon Pharmaceuticals shares in Q1 2016, an estimated $137K.
Arden Trust first reported a position in Lexicon Pharmaceuticals in Q4 2015 and held it in 1 quarter.
Arden Trust's Lexicon Pharmaceuticals position peaked at $137K in Q4 2015.
132 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q1 2016.

Based on Arden Trust's 13F filing for Q1 2016, filed 18 May 2016.